希望组 operates a comprehensive third-generation sequencing technology platform, claiming the world’s largest ONT sequencing center with 20 GridION X5, 1 PromethION, 6 PacBio Sequel and 2 Bionano Saphyr instruments. The company has built a large-memory high-performance computing platform and integrated third-generation sequencing analysis pipelines onto Alibaba Cloud and Huawei Cloud to provide global compute and storage services. 希望组 runs two brands—“未来组” for research users (accumulating experience since 2011) and “希望组” for clinical users—and focuses on applications in genetic disease testing, oncology diagnosis, assisted reproduction, and microbiome research. The firm emphasizes both scientific-service work and clinical translation, and it holds related R&D and IP accumulation in these areas. Recent technological advances (PacBio and ONT improvements and PromethION cost reductions) have enabled broader application of long-read sequencing in SNV, SV and methylation analyses, which 希望组 plans to leverage. The company intends to increase platform and R&D investment, productize clinical applications, strengthen upstream partnerships, and expand its international scientific and medical services.

Total raised

$15M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2021